Artículos por temáticas

Costs of Underfunding Brain Development

Tsuji M, Molnár Z.

Dev Neurosci. 2025 May 30:1-27. doi: 10.1159/000546688. Online ahead of print.

Decoding crosstalk between neurotransmitters and α-synuclein in Parkinson's disease: pathogenesis and therapeutic implications

Guan L, Lin L, Ma C, Qiu L.

Ther Adv Neurol Disord. 2025 Jun 5;18:17562864251339895. doi: 10.1177/17562864251339895. eCollection 2025.

Mitochondrial Dysfunction is a Crucial Immune Checkpoint for Neuroinflammation and Neurodegeneration: mtDAMPs in Focus

Mishra Y, Kumar A, Kaundal RK.

Mol Neurobiol. 2025 Jun;62(6):6715-6747. doi: 10.1007/s12035-024-04412-0. Epub 2024 Aug 8.

Constipation and risk of cognitive impairment and dementia in adults: a systematic review and meta-analysis

Wang Q, Yi T, Jiang X.

Front Neurol. 2025 Jun 4;16:1600952. doi: 10.3389/fneur.2025.1600952. eCollection 2025.

[Drug-induced Parkinsonism: A Psychiatric Perspective]

Kitada S, Tsuboi T.

Brain Nerve. 2025 Jun;77(6):707-713. doi: 10.11477/mf.188160960770060707.

Acute Febrile Encephalopathy with Rigidity

Kelly DM, Kelleher EM.

J Intensive Care Med. 2025 May 30:8850666251345448. doi: 10.1177/08850666251345448. Online ahead of print.

Brain O-GlcNAcylation: Bridging physiological functions, disease mechanisms, and therapeutic applications

Chen L, Jiang H, Licinio J, Wu H.

Mol Psychiatry. 2025 Jun;30(6):2754-2772. doi: 10.1038/s41380-025-02943-z. Epub 2025 Mar 3.

Role of LRRK2 in axonal transport and Parkinson's disease

Twellsieck B, Boecker CA.

Biochem J. 2025 Jun 25;482(13):BCJ20253133. doi: 10.1042/BCJ20253133.

Improving mitochondria-associated endoplasmic reticulum membranes integrity as converging therapeutic strategy for rare neurodegenerative diseases and cancer

Cagalinec M, Mohd A, Borecka S, Bultynck G, Choubey V, Yanovsky-Dagan S, Ezer S, Gasperikova D, Harel T, Jurkovicova D, Kaasik A, Liévens JC, Maurice T, Peviani M, Richard EM, Skoda J, Skopkova M, Tar

Biochim Biophys Acta Mol Cell Res. 2025 Jun;1872(5):119954. doi: 10.1016/j.bbamcr.2025.119954. Epub 2025 Apr 9.

Beyond a syndrome: a mechanism for depression in Parkinson's disease

Le Heron C, Chong TTJ.

Brain. 2025 Jun 3;148(6):1859-1861. doi: 10.1093/brain/awaf165.

Reported Symptoms in Prodromal and Early Motor Parkinson's Disease: A Scoping Review on the Patient Perspective

Saade J, van Wyk A, Stebbins GT, Mestre TA.

Mov Disord Clin Pract. 2025 Jun;12(6):721-733. doi: 10.1002/mdc3.70007. Epub 2025 Mar 3.

Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau

Chisholm TS, Hunter CA.

Chem Rev. 2025 Jun 11;125(11):5282-5348. doi: 10.1021/acs.chemrev.4c00838. Epub 2025 May 6.

The effectiveness of action observation and motor imagery in freezing of gait, speed, physical function and balance in Parkinson's disease: a systematic review and meta-analysis

Lahuerta-Martín S, Ceballos-Laita L, Jiménez-Del-Barrio S, Llamas-Ramos R, Llamas-Ramos I, Mingo-Gómez MT.

Physiother Theory Pract. 2025 Jun;41(6):1297-1315. doi: 10.1080/09593985.2024.2404600. Epub 2024 Sep 19.

Effects of virtual reality cognitive training on executive function and prospective memory in Parkinson's disease and healthy aging

Fiorenzato E, Zabberoni S, De Simone MS, Costa A, Tieri G, Taglieri S, Peppe A, Carlesimo GA, Caltagirone C, Antonini A, Cona G.

J Neurol Sci. 2025 Jun 15;473:123507. doi: 10.1016/j.jns.2025.123507. Epub 2025 Apr 14.

Advancing Parkinson's diagnosis: seed amplification assay for α-synuclein detection in minimally invasive samples

Carrazana E, Montalbán-Gutiérrez L, Chana-Cuevas P, Salvadores N.

Mol Cell Biochem. 2025 Jun;480(6):3297-3314. doi: 10.1007/s11010-024-05190-y. Epub 2025 Jan 6.